Cubist Systematic Strategies’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-32,834
Closed -$2.24M – 4984
2022
Q3
$2.24M Sell
32,834
-29,655
-47% -$1.64M 0.01% 1890
2022
Q2
$2M Buy
62,489
+51,598
+474% +$1.51M 0.01% 1869
2022
Q1
$377K Sell
10,891
-26,899
-71% -$804K ﹤0.01% 2703
2021
Q4
$1.11M Sell
37,790
-140,009
-79% -$4.34M 0.01% 1842
2021
Q3
$4.53M Buy
177,799
+92,896
+109% +$2.73M 0.06% 515
2021
Q2
$2.97M Buy
84,903
+7,269
+9% +$284K 0.03% 836
2021
Q1
$3.16M Buy
77,634
+23,095
+42% +$1.06M 0.04% 714
2020
Q4
$2.36M Buy
54,539
+21,347
+64% +$1.05M 0.03% 845
2020
Q3
$1.83M Sell
33,192
-18,295
-36% -$1.16M 0.03% 965
2020
Q2
$3.25M Buy
51,487
+32,906
+177% +$2.26M 0.06% 539
2020
Q1
$949K Sell
18,581
-4,668
-20% -$313K 0.03% 869
2019
Q4
$1.85M Buy
23,249
+10,144
+77% +$601K 0.03% 794
2019
Q3
$636K Sell
13,105
-4,257
-25% -$222K 0.01% 1179
2019
Q2
$913K Buy
+17,362
New +$998K 0.02% 1099
2018
Q4
– Sell
-9,410
Closed -$358K – 2349
2018
Q3
$358K Buy
9,410
+1,308
+16% +$57.9K 0.02% 1048
2018
Q2
$366K Buy
+8,102
New +$369K 0.02% 960
2018
Q1
– Sell
-733
Closed -$29K – 2143
2017
Q4
$29K Sell
733
-5,786
-89% -$216K ﹤0.01% 1823
2017
Q3
$202K Sell
6,519
-1,686
-21% -$47.4K 0.01% 1439
2017
Q2
$224K Buy
8,205
+3,991
+95% +$119K 0.01% 1223
2017
Q1
$155K Buy
+4,214
New +$106K 0.01% 1278
2016
Q2
– Sell
-5,665
Closed -$90K – 1937
2016
Q1
$90K Buy
+5,665
New +$101K 0.01% 1412

Other funds holding GBT

Cubist Systematic Strategies's GBT Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 32,834 shares — an estimated $2.24M sold.

Cubist Systematic Strategies first reported a position in GBT in Q1 2016 and held it in 21 quarters. The position peaked at $4.53M in Q3 2021. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 32,834 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.24M.
  • Cubist Systematic Strategies first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 21 quarters.
  • Cubist Systematic Strategies's Global Blood Therapeutics, Inc. position peaked at $4.53M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.